Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FREEDOM: Efanesoctocog Alfa in Severe Haemophilia A
NCT05817812Phase 3Completed
- Sponsor
- Sobi
- Start
- Jul 2023
- Primary completion
- Jun 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 14
01
Overview
A Phase 3 trial of efanesoctocog alfa in hemophilia A, sponsored by Sobi. Started Jul 2023; status: completed.
02
Drugs
efanesoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT05817812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05817812.